The positive biomarker data for BGE-102 supports its potential as a best-in-class oral NLRP3 inhibitor, with upcoming Phase 2a readouts in 2026 serving as key catalysts. The expanded indication into DME diversifies clinical risk. While fundamentals remain pre-revenue and loss-making, the strong cash position de-risks near-term execution. Traders should monitor Phase 2a initiation and data timelines as potential upside triggers.
Price Chart
Executive Summary
BioAge Labs reported its full-year 2025 financial results alongside key clinical and corporate updates, including positive Phase 1 data for its NLRP3 inhibitor BGE-102, expansion into ophthalmology, and completion of a $132.3 million follow-on offering. The company now has $285.1 million in cash, funding operations through 2029. While collaboration revenue rose to $9.0 million, R&D and G&A expenses increased, resulting in a net loss of $80.6 million.
Key Financial Metrics
Key Facts
- Positive interim Phase 1 data for BGE-102 showed 86% median reduction in hsCRP, 58% in IL-6, and 30% in fibrinogen in obese patients with elevated inflammation.
- Phase 2a proof-of-concept trial in cardiovascular risk to initiate in 1H 2026; data expected in 2H 2026.
- BGE-102 program expanded into diabetic macular edema (DME), with Phase 1b/2a trial planned for mid-2026.
- Completed upsized follow-on offering raising $132.3 million in gross proceeds, strengthening cash position.
- Cash, cash equivalents, and marketable securities totaled $285.1 million as of December 31, 2025, sufficient to fund operations through 2029.
- Collaboration revenue was $9.0 million in 2025 (vs. $0 in 2024), driven by the Novartis partnership.
- R&D expenses rose to $73.9 million (from $59.0 million in 2024), primarily due to BGE-102 and APJ agonist programs, partially offset by termination of azelaprag.
- Net loss was $80.6 million in 2025 ($2.24 per share), compared to $71.1 million ($6.63 per share) in 2024.
Financial Impact
Revenue increased by $9.0 million due to Novartis collaboration, but R&D and G&A expenses rose by $14.9M and $8.6M respectively, leading to a larger net loss. However, the $132.3M capital raise significantly extends runway.
Risk Factors
- Clinical development risk: BGE-102 is still in early stages; Phase 2a data may not confirm efficacy.
- Dilution from the follow-on offering: 6.8M shares issued, increasing share count by ~18%.
- High cash burn: Despite extended runway, R&D spending is accelerating, and future financings may be needed before commercialization.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3261303 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 16, 2026 15w ago | Press Release | $20.49 $8.65 | ▼ −57.78% | ▼ −58.78% | $6.72 (−67.20%) |
May 8, 2026 21w ago | 8-K | $17.99 $11.20 | ▼ −37.74% | ▼ −42.58% | $6.72 (−62.65%) |
Apr 21, 2026 23w ago | DEFA14A | $18.36 $22.81 | ▲ +24.24% | ▲ +19.46% | $6.72 (−63.40%) |
Apr 21, 2026 23w ago | Press Release | $19.61 $22.16 | ▲ +13.00% | ▲ +6.10% | $6.72 (−65.73%) |
Apr 1, 2026 26w ago | 144 | $17.73 $24.95 | ▲ +40.72% | ▲ +27.34% | $6.72 (−62.10%) |
Mar 24, 2026 27w ago | Press Release | $16.11 $20.77 | ▲ +28.93% | ▲ +14.60% | $6.72 (−58.29%) |
Mar 2, 2026 30w ago | Court Ruling | $21.71 $16.95 | ▼ −21.93% | ▼ −31.26% | $6.72 (−69.05%) |
Feb 28, 2026 30w ago | Institutional Cluster | $21.71 $16.20 | ▼ −25.38% | ▼ −34.71% | $6.72 (−69.05%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access